Sign up for the PROMACTA Patient Support Program
Access resources that may help you manage your cITP treatment
Have other treatments, such as steroids or IVIg, not worked to keep your platelet levels stable or have they caused too many side effects?
PROMACTA® (eltrombopag) may be an option to treat your cITP. Once-daily PROMACTA can quickly boost your platelet counts and keep them stable over time.
PROMACTA has been studied extensively in more people with cITP than any other drug of its class,* including 3 clinical trials for adults and 1 long-term study that lasted 7 years. More than 700 adults were enrolled in 3 separate studies, and 302 of them went on to participate in the long-term study, which was the longest and largest ever run in cITP.
Did you know PROMACTA is also proven to work for children with cITP as young as 1 year old? Go here to learn about PROMACTA for cITP in children.
PROMACTA may help you reach your platelet goal
The proof is in the clinical studies of adults with cITP.
In a clinical trial of 117 adults with cITP...
PROMACTA works fast:
of people reached their target platelet count as early as Day 8
of people reached their target platelet goal as early as 2 weeks
responded at Day 43 (primary study end point)
In a clinical trial of 302 adults with cITP...
PROMACTA keeps working:
PROMACTA maintained platelet counts up to 7 years—the longest results ever reported in cITP
Other ways PROMACTA may help:
- At Day 15, PROMACTA showed a 64% reduction in serious bleeding, from 22% to 8%
- At 1 year, PROMACTA showed a 76% reduction in serious bleeding, from 17% to 4%
- 34% of people permanently stopped taking at least 1 ITP medication, usually steroids
- At 5 years, in questionnaires used in the long-term trial, 80% of people with cITP self-reported less fatigue, bleeding, and bruising
A wide range of people with cITP were included in these clinical studies.
|
Data from 3 clinical studies and 1 long-term study of PROMACTA |
|
|
% of Males |
31-39% |
|
% of Females |
61-69% |
|
Median Age |
47-50 years old |
|
Average Starting |
Less than 30,000/mcL |
Did you know? Chronic ITP affects women more than men at a rate of almost 2:1.
Extensively studied in ~900 people with cITP (ages 1 to 85)
- 730 adults
- 159 children
In clinical trials, consistently proven across patient types, no matter their age, sex, race, starting platelet count, number of medications they are taking for their ITP, or whether or not they’ve had their spleen removed
PROMACTA has demonstrated consistent safety, study after study
No other cITP drug has been studied more than PROMACTA:
- The safety of PROMACTA was established in ~900 people, ranging in age from 1 to 85
- No single side effect occurred in more than 10% of people across 4 clinical studies
- PROMACTA may cause serious side effects including liver problems, blood clots, and cataracts
- The most common side effects of PROMACTA in adults and children include:
- low red blood cell count (anemia)
- nausea
- fever
- abnormal liver function tests
- cough
- tiredness
- headache
- diarrhea
- See additional safety information in the full Prescribing Information at https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/promacta.pdf
- At 6 years of treatment, no new or increased side effects were seen in comparison to the short-term trials
Now that you know PROMACTA has been proven to work for a wide range of people in clinical trials, find out how it works in your body to boost platelets. Click here.
What to expect when you’re starting PROMACTA
Learning how to make a new medicine part of your routine can take time. Each of the patients below had a different concern about starting treatment with PROMACTA. While everyone is unique, you may find it helpful to learn about other people’s experiences.
Take a look at the concerns below. Does anything sound familiar? See if something rings true for you.
Select each patient to learn more about his or her experience with taking PROMACTA.
When I first started taking PROMACTA, sometimes I took my medicine with food. But my doctor explained that for PROMACTA to work best, it should be taken on an empty stomach. My doctor also told me that I shouldn’t be taking calcium-rich products around the time I take my medication. Now I take PROMACTA without food and avoid high-calcium items around my dosing times, so I can get the full benefit of PROMACTA.
I’ll be the first to admit that I’m not the most patient person in the world. So when I started on PROMACTA, I wanted to know immediately if it was working. But because you may not feel any difference, especially in the beginning, it’s hard to know. That’s why I liked having regular blood tests. In the beginning, you’ll go every week to the doctor for a platelet count check, so your doctor can see if PROMACTA is working. This was great because I got to see the progress in my numbers right from the start, and because my doctor also checked my liver function, I felt comfortable knowing that it was safe for me to stay on PROMACTA. Now that my PROMACTA dose is set, I only need to get blood tests.
When my doctor first mentioned PROMACTA, I have to admit that I was uncertain about trying another medicine, especially when my last medication was not getting my platelet counts to the level my doctor was looking for. But my doctor reassured me by explaining that PROMACTA actually works with my body to boost the number of platelets being made—and keeps them at stable levels over time. And the fact that PROMACTA is a once-daily tablet means I can take it at the time that works best for me, wherever I am, without having to go into the doctor’s office for a weekly injection.
The above are patient portrayals.
Being diagnosed with cITP
Do you share any of the same thoughts or concerns as Carol, Tom, or Alice? Click here to read how other people have reacted to being told that they have cITP.
TPO-RA, thrombopoietin receptor agonist.
*PROMACTA belongs to the TPO-RA class.
